Dr. Peter Leander is Regional Chief Radiology Officer, Skåne Region, Associate Professor in radiology at Lund University, Chairman of the Swedish Society of Radiology, and member of the Contrast Media Safety Committee under the European Society of Urogenital Radiology, ESUR. Dr. Leander has more than 20 years of experience in general radiology, a PhD in liver-specific contrast media for MRI and CT and significant experience with contrast media research.
"Peter Leander has extensive expertise and understanding of the clinical use and needs in the area of MRI and MRI contrast agents. He will be a very valuable addition to the board of directors, especially as we move towards clinical phase with SPAGOs MRI contrast agent", says Maria Fors, CEO of Accelerator Nordic AB.
SPAGO Imaging is developing a novel, nanoparticle based, tumor selective MRI contrast agent, SPAGO Pix, which has the potential to significantly improve cancer diagnosis. The unique features of SPAGO Pix have the potential to allow visualization of small soft tissue tumors and metastases with increased specificity.
According to WHO, over 12 million patients are diagnosed with cancer every year worldwide, a figure that is expected to more than double by 2030. Early and accurate diagnosis is often critical for efficient treatment and long term survival. None of today's tumor imaging methods is of sufficiently high quality to meet all necessary requirements in terms of sensitivity, specificity, safety, and cost.
For additional information, please contact Maria Fors, CEO Accelerator Nordic AB, +46 76 119 1983.
Accelerator Nordic AB is a group of Life Science companies focused on Imaging Software and Medical Nanotechnology. Accelerator's subsidiaries have exposure towards large growth markets such as oncology, orthopedics, and diagnostics. Accelerator Nordic is publicly traded on the Aktietorget exchange in Stockholm, Sweden. For more information please visit, www.acceleratorab.se